LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company,
announced that its lead drug candidate PB272 (neratinib) will be
featured in 11 poster presentations at the 2016 San Antonio Breast
Cancer Symposium (SABCS), December 6 - 10, 2016, in San Antonio, Texas.
Abstracts are available to the public online on the SABCS website: www.sabcs.org.
Details of the poster and poster discussion presentations are as follows: